Goldman Sachs analyst David Roman initiated coverage of iRhythm Technologies with a Neutral rating and $78 price target The firm is constructive on the long-term continuous monitoring market but sees potential risk to consensus estimates for iRhythm. The potential for downside to consensus revenue estimates and long-term sales guidance along with regulatory uncertainty leads to a balanced risk/reward for the shares, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- iRhythm price target raised to $137 from $122 at Canaccord
- iRhythm received regulatory approval from Japanese PMDA for Zio ECG system
- iRhythm unveils data on real-world performance of Zio Monitor
- iRhythm Technologies Strikes Advanced Tech Licensing Deal
- iRhythm signs exclusive license agreement with BioIntelliSense